The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial of its experimental drug CagriSema — a combination of semaglutide and a medicine called cagrilintide. People on CagriSema lost about 23% of their body weight in a 68-week study, outperforming both drugs when taken alone.
Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...
"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...
While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.
Following his massive 55-kilo transformation, Ram Kapoor claimed he was flooded with questions on whether he took any ...
Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
According to the journal JAMA Health Forum, prescription fills for Ozempic increased by more than 400% between January 2021 ...
Surgical tweaks for “Ozempic face” are on the rise. The latest report from AAFPRS reveals a 50% increase in facial fat ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback